Genetic and genomic alterations differentially dictate low-grade glioma growth through cancer stem cell–specific chemokine recruitment of T cells and microglia
- 3 May 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 21 (10) , 1250-1262
Abstract
Background: One of the clinical hallmarks of low-grade gliomas (LGGs) arising in children with the neurofibromatosis type 1 (NF1) cancer predisposition syndrome is significant clinical variability with respect to tumor growth, associated neurologic deficits, and response to therapy. Numerous factors could contribute to this clinical heterogeneity, including the tumor cell of origin, the specific germline NF1 gene mutation, and the coexistence of additional genomic alterations. Since human specimens are rarely acquired, and have proven difficult to maintain in vitro or as xenografts in vivo, we have developed a series of Nf1 mutant optic glioma mouse strains representing each of these contributing factors. Methods: Optic glioma stem cells (o-GSCs) were generated from this collection of Nf1 genetically engineered mice, and analyzed for their intrinsic growth properties, as well as the production of chemokines that could differentially attract T cells and microglia. Results: The observed differences in Nf1 optic glioma growth are not the result of cell autonomous growth properties of o-GSCs, but rather the unique patterns of o-GSC chemokine expression, which differentially attract T cells and microglia. This immune profile collectively dictates the levels of chemokine C-C ligand 5 (Ccl5) expression, the key stromal factor that drives murine Nf1 optic glioma growth. Conclusions: These findings reveal that genetic and genomic alterations create murine LGG biological heterogeneity through the differential recruitment of T cells and microglia by o-GSC–produced chemokines, which ultimately determine the expression of stromal factors that drive tumor growth.Keywords
Funding Information
- National Cancer Institute (1-R01-CA214146-01)
- National Institute of Neurological Disorders and Stroke (1-R35-NS07211-01)
- James S. McDonnell Foundation
This publication has 43 references indexed in Scilit:
- Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterationsActa Neuropathologica, 2018
- Optic Pathway Gliomas in Neurofibromatosis Type 1Journal of Child Neurology, 2017
- Mutant IDH1 regulates the tumor-associated immune system in gliomasGenes & Development, 2017
- Pilocytic astrocytoma and glioneuronal tumor with histone H3 K27M mutationActa Neuropathologica Communications, 2016
- Loss of CX3CR1 increases accumulation of inflammatory monocytes and promotes gliomagenesisOncotarget, 2015
- An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral CortexThe Journal of Neuroscience, 2014
- The challenge of intratumour heterogeneity in precision medicineJournal of Internal Medicine, 2014
- Tumour-infiltrating CD4+ and CD8+ lymphocytes as predictors of clinical outcome in gliomaBritish Journal of Cancer, 2014
- Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytomaNature Genetics, 2013
- Tandem Duplication Producing a Novel Oncogenic BRAF Fusion Gene Defines the Majority of Pilocytic AstrocytomasCancer Research, 2008